Unknown

Dataset Information

0

CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma.

ABSTRACT: Epithelial ovarian cancer (EOC) is the deadliest gynecological malignancy. EOC control remains difficult, and EOC patients show poor prognosis regarding metastasis and chemotherapy resistance. The aim of this study was to estimate the effect of CXCR4 knockdown-mediated reduction of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) stemness and enhancement of chemotherapy sensitivity in EOC. Mechanisms contributing to these effects were also explored. Our data showed distinct contribution of CXCR4 overexpression by dependent PI3K/Akt/mTOR signaling pathway in EOC development. CXCR4 knockdown resulted in a reduction in CSCs and EMT formation and enhancement of chemotherapy sensitivity in tumor cells, which was further advanced by blocking CXCR4-PI3K/Akt/mTOR signaling. This study also documented the critical role of silencing CXCR4 in sensitizing ovarian CSCs to chemotherapy. Thus, targeting CXCR4 to suppress EOC progression, specifically in combination with paclitaxel (PTX) treatment, may have clinical application value.

SUBMITTER: Zi D 

PROVIDER: S-EPMC9217704 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma.

Zi Dan D   Li Qing Q   Xu Cheng-Xiong CX   Zhou Zhi-Wei ZW   Song Guan-Bin GB   Hu Cheng-Bin CB   Wen Fang F   Yang Han-Lin HL   Nie Lei L   Zhao Xing X   Tan Jun J   Zhou Shu-Feng SF   He Zhi-Xu ZX  

Aging 20220609 11

Epithelial ovarian cancer (EOC) is the deadliest gynecological malignancy. EOC control remains difficult, and EOC patients show poor prognosis regarding metastasis and chemotherapy resistance. The aim of this study was to estimate the effect of CXCR4 knockdown-mediated reduction of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) stemness and enhancement of chemotherapy sensitivity in EOC. Mechanisms contributing to these effects were also explored. Our data showed distinct c  ...[more]

Similar Datasets

Unknown GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mTOR pathway.
| S-EPMC10901536 | biostudies-literature
Unknown Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.
| S-EPMC4088997 | biostudies-literature
Unknown Knockdown of RASD1 improves MASLD progression by inhibiting the PI3K/AKT/mTOR pathway.
| S-EPMC11681670 | biostudies-literature
Unknown The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
| S-EPMC4302085 | biostudies-literature
Unknown Compound C Inhibits Ovarian Cancer Progression via PI3K-AKT-mTOR-NFκB Pathway.
| S-EPMC9600774 | biostudies-literature
Unknown DDTC Suppresses Ovarian Cancer Development via the PI3K/AKT/mTOR Signaling Pathway.
| S-EPMC9377914 | biostudies-literature
Unknown Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
| S-EPMC5833539 | biostudies-literature
Unknown PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours.
| S-EPMC5529984 | biostudies-other
Unknown Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway.
| S-EPMC10466839 | biostudies-literature
Unknown Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
| S-EPMC3604032 | biostudies-literature